Literature DB >> 28982356

Correction to: Adverse events following immunization with pentavalent vaccine: experiences of newly introduced vaccine in Iran.

Manoochehr Karami^1,2, Pegah Ameri³, Jalal Bathaei⁴, Zeinab Berangi³, Tahereh Pashaei⁵, Ali Zahiri⁴, Seyed Mohsen Zahraei⁶, Hussein Erfani⁴, Koen Ponnet^7,8.

Abstract

Entities: Disease Species

Year: 2017 PMID： 28982356 PMCID： PMC5628489 DOI： 10.1186/s12865-017-0228-6

Source DB: PubMed Journal: BMC Immunol ISSN： 1471-2172 Impact factor: 3.615

× No keyword cloud information.

Erratum

After publication of the original article [1], the authors noticed that the percentages in Table 2 were incorrect.

Table 2

Comparison of the cumulative incidence rates of complications in the first, second and third doses of the vaccination in children

Adverse events	Incidence (per 100 children)Vaccine dose			P-value(1^st and 2^nd dose comparison)	P-value(2^nd and 3^rddose comparison)
Adverse events	1^st dose(2 months) N = 373	2^nddose(4 months) N = 372	3^rddose(6 months) N = 374	P-value(1^st and 2^nd dose comparison)	P-value(2^nd and 3^rddose comparison)
Swelling	79(21.2)	50(13.4)	48(12.8)	0.003	0.068
Redness	50(13.4)	30(8.1)	43(11.5)	0.026	0.679
Pain	190(50.9)	143(38.4)	62(16.6)	0.001	0.162
Mild fever	45(12.1)	33(8.9)	63(16.8)	0.068	<0.001
High fever	1(0.3)	0(0)	0(0)	0.388	NA
Drowsiness	83(22.3)	72(19.4)	70(18.7)	0.310	0.725
Anorexia	65(17.4)	51(13.7)	52(13.9)	0.126	1
Restlessness	35(9.4)	115(30.9)	119(31.8)	<0.001	0.766
Vomiting	16(4.3)	19(5.1)	17(4.5)	0.510	0.510
Long-term crying	24(6.4)	16(4.3)	22(5.9)	0.210	0.510
Encephalopathy	0(0)	0(0)	0(0)	NA	NA
Convulsion	0(0)	0(0)	0(0)	NA	NA
History of convulsion	0(0)	1(0.3)	2(0.5)	0.387	0.488
Family history of convulsion	0(0)	14(3.8)	6(1.6)	<0.001	0.074

NA not applicable

Comparison of the cumulative incidence rates of complications in the first, second and third doses of the vaccination in children NA not applicable The correct version of Table 2 is published in this erratum.

1 in total

1. Adverse events following immunization with pentavalent vaccine: experiences of newly introduced vaccine in Iran.

Authors: Manoochehr Karami; Pegah Ameri; Jalal Bathaei; Zeinab Berangi; Tahereh Pashaei; Ali Zahiri; Seyed Mohsen Zahraei; Hussein Erfani; Koen Ponnet
Journal: BMC Immunol Date: 2017-08-23 Impact factor: 3.615

1 in total